Recommended patient-reported core set of symptoms and quality-of-life domains to measure in ovarian cancer treatment trials (Q33947886)

30 July 2017

title

Recommended patient-reported core set of symptoms and quality-of-life domains to measure in ovarian cancer treatment trials (English)

1 reference

30 July 2017

1 reference

1 reference

3

David Cella

1 reference

30 July 2017

Kristine A Donovan

1

1 reference

30 July 2017

Heidi S Donovan

2

1 reference

30 July 2017

Martha E Gaines

4

1 reference

30 July 2017

Richard T Penson

5

1 reference

30 July 2017

Steven C Plaxe

6

1 reference

30 July 2017

Vivian E von Gruenigen

7

1 reference

30 July 2017

Deborah Watkins Bruner

8

1 reference

30 July 2017

Bryce B Reeve

9

1 reference

30 July 2017

Lari Wenzel

10

1 reference

30 July 2017

language of work or name

English

0 references

publication date

8 July 2014

1 reference

Journal of the National Cancer Institute

30 July 2017

published in

1 reference

30 July 2017

volume

106

1 reference

30 July 2017

issue

7

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110471

30 July 2017

1 reference

28 July 2018

Cancer statistics, 2012

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110471

Assessing the Symptoms of Cancer Using Patient-Reported Outcomes (ASCPRO): searching for standards

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110471

A comparison of quality-of-life domains and clinical factors in ovarian cancer patients: a Gynecologic Oncology Group study

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110471

Current status on biologic therapies in the treatment of epithelial ovarian cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110471

A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110471

Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110471

Validation of FACT/GOG-AD subscale for ovarian cancer-related abdominal discomfort: a Gynecologic Oncology Group study

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110471

Evaluation of the Symptom Representation Questionnaire (SRQ) for assessing cancer-related symptoms

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110471

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110471

Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110471

Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110471

A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada [...]

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110471

Standard treatment in advanced ovarian cancer in 2005: the state of the art.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110471

Frequency of symptoms of ovarian cancer in women presenting to primary care clinics

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110471

Quality of life in ovarian cancer patients receiving chemotherapy

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110471

The Functional Assessment of Cancer Therapy scale: development and validation of the general measure

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110471

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110471

Maintenance therapy in advanced ovarian cancer: progression-free survival and clinical benefit.

28 July 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU128

Reliability and validity of the functional assessment of cancer therapy-ovarian

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU128

Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU128

Optimism, distress, health-related quality of life, and change in cancer antigen 125 among patients with ovarian cancer undergoing chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU128

Patient-provider communication and perceived control for women experiencing multiple symptoms associated with ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU128

A new index of priority symptoms in advanced ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU128

Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU128

Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU128

Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU128

A phase II trial of oral capecitabine in patients with platinum--and taxane--refractory ovarian, fallopian tube, or peritoneal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU128

Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU128

Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU128

An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU128

Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU128

Development of a European Organization for Research and Treatment of Cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: a progress report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU128

Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU128

The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU128

21 January 2018

Identifiers

DOI

10.1093/JNCI/DJU128

1 reference

30 July 2017

1 reference

30 July 2017

1 reference